Novartis Oncology published a study by a group at Virginia Tech showing that choline in two randomized, double-blind, placebo-controlled crossover trials in healthy adults increased plasma TMAO by 400 percent acutely and 110 percent over four weeks.

At Novartis, our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. At Novartis, we focus on five key cancer areas where we have identified patient needs and promise within our portfolio - breast cancer, lung cancer, melanoma, kidney cancer and hematology. As a leader in oncology, Novartis offers a portfolio treating more than 25 conditions worldwide and approximately 30 compounds in development. We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are reimagining medicine. See our community guidelines: https://go.novartis.social/4bqbjuA